Jonathan Gilbert

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Bridger Management LLC (Bridger) is a registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Roberto Mignone in 2000 and is a direct subsidiary of Bridger Management II LP. Bridger serves as the investment adviser, with discretionary trading authority, to private, pooled investment vehicles, the securities of which are offered through a private placement memorandum to accredited investors.

Microbion Corp. develops topical microbial therapeutic products. It safeguards human health by overcoming infections, antibiotic resistance, and microbial biofilms with safe, effective anti-infective products. The firm is developing MBN-101 as the first product in a new class for the treatment of antibiotic-resistant and difficult to treat infections. The company was founded by Brett H. Baker and is headquartered in Bozeman, MT.

PhysIQ, Inc. provides proprietary predictive analytics for human physiology. It designs, develops and commercializes predictive analytics technologies to monitor the health of complex systems. The company was founded by Matt R. Pipke and Gary W. Conkright in 1999 and is headquartered in Naperville, IL.

Polaris Partners is an Independent Venture Capital firm founded in 1996 by Stephen D. Arnold, Jonathan A. Flint and Terrance G. McGuire. Polaris Partners is headquartered in Waltham.

Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts.

NanoDimension Management Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town.

Community Servings is a non-profit organization that provides food and nutrition programs to individuals and families living with critical and chronic illnesses. It offers meal delivery, nutrition services, and program initiatives, covering: job trainings, international advocacies, social enterprise, and sustainable agriculture. The company was founded in 1989 and is headquartered in Jamaica Plain, MA.

Pulse Therapeutics, Inc. provides medical devices to destroy blood clots. Its devices help in treating the stroke, heart disease and other conditions. Its products include MED System which helps in dissolve blood clots. The company was founded by Francis M. Creighton and Rogers Ritter in 2008 and is headquartered in St. Louis, Mo.

Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA.

Eloxx Pharmaceuticals Ltd. provides biopharmaceutical research and development services. The firm specializes in the discovery, development, and commercialization of drug compounds for the treatment of genetic diseases. It focuses on the treatment of diseases caused by nonsense mutations, including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, and Tay-Sachs Hurler syndrome. Its focus areas encompass clinical drug development and target drugs discovery programs. The company was founded by Silvia Noiman and Shmuel Tuvia in 2013 and is headquartered in Herzliya, Israel.

Lyndra Therapeutics, Inc. develops software technology for oral drug formulations. It offers pharmacology, therapeutic impact, reduced pill burden, and reduced care giver burden. The company was founded by Amy W. Schulman, Carlo Giovanni Traverso, Andrew Bellinger, and Robert S. Langer Jr. in 2015 and is headquartered in Watertown, MA.

CathWorks Ltd. develops medical devices for the interventional cardiology market. Its technology is based on processing visual information and automatic multi-layered algorithms. The company was founded by Guy Lavi and Ifat Lavi in 2013 and is headquartered in Raanana, Israel.

Enclear Therapies, Inc. develops and manufactures novel device-based therapies to treat patients. The firm device is developed to treat and halt the progression of neurodegenerative diseases by removing toxic proteins known to drive pathology. The company was founded by Anthony R. DePasqua, Jonathan J. Fleming, Kasper Roet, William B. Gormley and Kevin Eggan and is headquartered in Newburyport, MA.

Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA.

Part of Sonata Therapeutics, Inc., Inzen Therapeutics, Inc. is discovering and developing a novel class of medicines based on thanokine biology. The company is based in Cambridge, MA. Thanokine biology offers the potential for unprecedented approaches to prevent and treat cancer, fibrotic disorders, immune-inflammatory disorders, metabolic disorders, and degenerative diseases. Inzen's thanokine product platform applies advances in mass spectrometry and machine learning, novel probes, unique assays, genetic and chemical biological technologies to characterize thanokine biology at scale and create drug candidates. Inzen Therapeutics harnesses signals of the cellular microenvironment to treat serious diseases. The company was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann.

Partillion Bioscience Corp. is an American company that specializes in providing a functional single-cell biology reagent platform. The company's nanovial technology allows for single-cell secretion analysis and other research capabilities. The company was founded by Joseph Michael de Rutte and Dino Di Carlo, with Joseph Michael de Rutte serving as CEO since incorporation.

Airna, Inc. is an American company that focuses on the discovery and development of RNA editing therapeutics. Airna was founded by Thorsten Stafforst, Jin Billy Li, Tobias Merkle, Paul Vogel. The CEO is Kris Elverum.